Main Catalog

Found 81

Sort by

Member Free

Non-Member $30.00

340B Program Evolution: Understanding Impact on Payers

Contact Hours: 1.25. Participants should claim continuing pharmacy education (CPE) credit for this home study activity, only if they have not claimed credit for the live activity presented at AMCP Annual Meeting 2017.

340B

Member Free

Non-Member $30.00

AMCP Federal and State Legislative/Regulatory Update Home Study

Contact Hours: 1.0. In today’s world, healthcare legislation and regulation move at a staggering pace making it difficult for health professionals to keep up.

Law

Member Free

Non-Member $30.00

AMCP Headline Session: 2017–2018 Pharmaceutical Marketplace Trends

Not Accredited for CPE: Keeping abreast of industry trends and forecasts is vital to remaining competitive in the evolving managed care arena— especially because market predictions can shape the approach to managing the pharmacy benefit.

AMCP Headline Session 2018

Member Free

Non-Member $30.00

Best Practices in Combating Opioid Abuse, Misuse and Diversion: The Health Plan Perspective - Nexus 2017

Contact Hours: 1.5. The opioid epidemic in the United States continues to worsen. Roughly 91 Americans die each day from an opioid overdose.

Opioid

Member Free

Non-Member $30.00

Best Practices to Implementing Proactive Communications Between Manufacturers and Payers

Contact Hours: 1.25. The recent enactment of the 21st Century Cures Act, and specifically Section 3037 (Cures 3037), modernized provisions of the Food and Drug Administration Modernization Act of 1997, Section 114 (FDAMA 114).

Managed Care Regulation

Member Free

Non-Member $30.00

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.

Biosimilars

Member Free

Non-Member $30.00

Bracing for Impact: Preparing for the 2019 Specialty Drug Spend - Nexus 2017

Contact Hours: 1.5. The escalating cost of prescription drugs is an issue that continues to plague the U.S. health care system, accounting for 17% of the total health care spend in 2015.

Hospital/Health Systems

Member $15.00

Non-Member $30.00

Brand and Generic Drugs in Development

Contact Hours: 1.25. This session focuses on new and emerging brand-name drugs, as well as upcoming generic drug approvals.

Brand and Generic Drugs

Member Free

Non-Member $30.00

Budget Impact Models: How Payers Can Build and Validate - Nexus 2017

Contact Hours: 1.5. Budget impact models (BIMs) can be built and used by payers for many decisions, including changes to the formulary.

Hospital/Health Systems

Member $15.00

Non-Member $30.00

Checking In on Health Care Reform Efforts: What Do They Mean for Payers, Manufacturers and Patients?

Contact Hours: 1.5. While broader drug pricing reform efforts have taken the lion’s share of attention in health policy discourse over the past year, the Trump Administration has continued to move forward with implementing changes to the Affordable Care Act (ACA).

Health Care Reform HCA

Member Free

Non-Member $30.00

Coverage and Reimbursement for High Cost Curative Therapeutics: Does a Solution Exist? - Nexus 2018

Contact Hours: 1.5. More and more, managed care organizations are straddling the line between making new, innovative therapies available to their patients and ensuring they can cover the costs of these therapies.

Drug Pricing

Member $15.00

Non-Member $30.00

Developments, Research, Pipeline, and Applications of Gene Therapy - Annual 2019

Contact Hours: 0.75: Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.

Gene Therapy

Member Free

Non-Member $30.00

Encore: Approaches to Managed Care Contracting with Pharmaceutical Manufacturers

Drug Pricing

Member Free

Non-Member $30.00

End of an Era: Lessons Learned from 2018 CMS Audits, and Prep for the Future - Nexus 2018

Contact Hours: 1.5. Ready for that upcoming 2019 audit? Do you know how to prepare? If your answer is no, join this session to hear how health plans prepare for their audits and address corrective actions, as lessons learned from the 2018 audit season are discussed.

CMS

Member Free

Non-Member $30.00

Evaluating the Use of Cost Per QALY in the US Health Care System

Hospital/Health Systems

Member Free

Non-Member Free

Expanding the Managed Care Professional’s Digital Therapeutics IQ - Home Study

Contact Hours: 1.5. Digital therapeutics are expanding the boundaries of the types of therapies that health care decision-makers must be adept at evaluating.

Digital Health

Member Free

Non-Member $30.00

Experience and Lessons Learned in Biosimilar Uptake - Nexus 2018

Contact Hours: 1.5. Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation.

Biosimilars

Member $15.00

Non-Member $30.00

Fast and Furious: What is Driving the Specialty Spend?

Contact Hours: 1.5. In 2018, the United States spent an estimated $517 million on specialty drugs. While specialty medications make up only about 1–2 % of all prescriptions written, they account for nearly 50% of total drug spend.

Specialty Drug Spend

Member Free

Non-Member $30.00

Federal and State Legislative and Regulatory Update - Annual Meeting 2018

Contact Hours: 1.25. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to pharmacists and other managed care and specialty pharmacy professionals.

Law

Member $15.00

Non-Member $30.00

Federal and State Legislative and Regulatory Update - Annual Meeting 2019

Contact Hours: 1.25. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.

Law

Member Free

Non-Member $30.00

Federal and State Legislative and Regulatory Update - Nexus 2017

Contact Hours: 1.5. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.

Law

Member Free

Non-Member $30.00

Federal and State Legislative and Regulatory Update - Nexus 2018

Law

Member $15.00

Non-Member $30.00

Financial Models to Manage Drug Spend of Gene Therapy - Annual Meeting 2019

Contact Hours 1.0: Gene therapy techniques offer potential breakthroughs for patients with serious health conditions. They also are associated with significant short-term costs yet hold the promise of long-term savings.

Gene Therapy

Member $399.00

Non-Member $499.00

Fundamentals of Managed Care Pharmacy Certificate Program 2nd Edition - Professional Version

Contact Hours: 8.75 (0.875 CEUs). The Fundamentals of Managed Care Pharmacy Certificate Program provides a comprehensive introduction to basic concepts in managed care pharmacy.

Fundamentals of Managed Care Pharmacy

Member $199.00

Non-Member $249.00

Fundamentals of Managed Care Pharmacy Certificate Program 2nd Edition | Student Version

The Fundamentals of Managed Care Pharmacy Certificate Program provides a comprehensive introduction to basic concepts in managed care pharmacy.

Fundamentals of Managed Care Pharmacy

Member $15.00

Non-Member $30.00

How Continued Drug Shortages Compromise Patient Care

Contact Hours: 1.5. Providing safe and effective drug therapy has become extremely challenging during extended periods of drug shortages.

Drug Shortages

Member Free

Non-Member $30.00

Improving Star Ratings Through Focused Clinical Strategy and Targeted Outreach: Results from a Systematic Approach - Nexus 2018

Contact Hours: 1.5. Star Ratings continue to evolve as measure specifications, benchmarks and inclusion into the overall calculation continue to change under Medicare.

CMS

Member $15.00

Non-Member $30.00

Increasing Positive Outcomes: The Impact of Social Determinants of Health

Contact Hours: 1.5. There is a growing body of evidence that highlights how social determinants of health—socioeconomic status, education, physical environment, employment, and social support networks—play a large role in determining overall health outcomes.

Social Determinants

Member $15.00

Non-Member $30.00

Innovative Value-Based Contracting Approaches with Comprehensive Clinical Strategies

Contact Hours: 1.5. Innovative approaches to developing value-based contracts in the market need to be multi-faceted.

Value-Based Contracting

Member $15.00

Non-Member $30.00

Introduction to Gene Therapy: Key Terms, Concepts, and International Perspectives - Annual Meeting 2019

Contact Hours: 1.0 : Gene therapy is an investigational technique that offers exciting promise of curing many debilitating and potentially terminal diseases, such as cystic fibrosis, multiple sclerosis, hemophilia, sickle cell disease, and spinal muscular atrophy.

Gene Therapy

Member $15.00

Non-Member $30.00

It’s an ART: Formulary and Drug Use Management Strategies for HIV Medications - Annual 2019

Contact Hours: 1.25. As people with HIV age, the focus of disease management places more emphasis on the safety of long-term medication use and managing comorbidities. The advantages of safer, more efficacious medications also come with increased cost.

HIV

Member Free

Non-Member $30.00

Key Forces Driving Change in Oncology

Contact Hours: 1.25. Oncology practice is changing rapidly as new advances in innovation lead to new evidence and testing requirements, as well as treatment guidelines.

Oncology

Member Free

Non-Member $30.00

Managing Orphan Drugs for Rare Diseases: Challenges, Opportunities, and Value Assessment - Annual 2017

Contact Hours: 1.5. Managing Orphan Drugs for Rare Diseases: Challenges, Opportunities and Value Assessment.

Orphan Disease

Member $15.00

Non-Member $30.00

Managing Patients with Hemophilia: A Payer’s Perspective - Annual Meeting 2018

Contact Hours: 1.0. Thanks to significant improvements in the treatment of hemophilia, patients are living longer than ever before, with higher expectations for
near-normal quality of life.

Hemophilia

Member $15.00

Non-Member $30.00

Measuring Value of an IDN Specialty Pharmacy Therapy Management Program for Biologics

Contact Hours: 1.25: Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.

Specialty

Member Free

Non-Member $30.00

Medical Benefit Medication Management - Low Hanging Fruit to Complex Strategy - Nexus 2017

Contact Hours: 1.5. Are you up to speed on the latest industry best practices in managing your medical-benefit medications?

Hospital/Health Systems

Member Free

Non-Member $30.00

Medical Oncology Drug Cost Trends and Innovative, Practical Payer Management Strategies - Nexus 2018

Contact Hours: 1.5. Medical oncology drugs represent 35 to 47% percent of total medical benefit drug spend.

Oncology

Member $15.00

Non-Member $30.00

Medicare Formulary Updates Impact

Contact Hours: 1.25. The Centers for Medicare and Medicaid (CMS) continues to critically evaluate formulary regulations and guidance to help lower drug costs.

Medicare

Member Free

Non-Member $30.00

More than Meets the Eye–Value-Based Contracts are More Prevalent than We Think

Contact Hours: 1.25. As the U.S. health care system evolves from a volume-driven system to one that rewards value, there is growing interest in value-based payment arrangements.

Value-Based Contracting

Member Free

Non-Member Free

Opioid Use Disorder: Emerging Best Practices for Payer and Clinician Management of Patient Care - Home Study

Contact Hours: 1.0. Addressing opioid use disorder (OUD) is a top concern for public health improvement. It is important to keep up with current treatment options to optimally treat patients, and while treatments vary by patient.

Opioid

Member Free

Non-Member $30.00

Patient Review and Restriction Programs: Prescription Drug Monitoring Programs and the Need for Collaboration

Contact Hours: 1.25. Patient Review and Restriction (PRR) programs are commonly used by health plans in doctor’s offices to manage the excessive prescribing of controlled substances or services.

Hospital/Health Systems

Member Free

Non-Member $30.00

Patient-Reported Outcomes: A Primer for Managed Care Pharmacists

Patient Care

Member Free

Non-Member $30.00

Payer & Manufacturer Communications: What’s Changed & How Does it Impact Managed Care Pharmacy? - Nexus 2017

Contact Hours: 1.5. FDA released long-awaited draft guidance clarifying the Provisions of FDAMA 114 as updated by Cures 3037, and also outlined its current thinking around preapproval information exchange (PIE).

CMS

Member $15.00

Non-Member $30.00

Perspectives in Gene Therapy Management - Annual Meeting 2019

Contact Hours: 1.0. The potential for gene therapy to transform the treatment of a wide variety of health conditions has important implications for many stakeholders.

Gene Therapy

Member Free

Non-Member $30.00

Pharmacy Benefit Management—Staying Ahead of Your Competition

Contact Hours: 1.25. Consolidations, acquisitions and partnerships across the health care spectrum have led to a highly competitive pharmacy benefit management (PBM) market.

Pharmacy Benefit Design

Member $15.00

Non-Member $30.00

Preventative Treatment for Alzheimer’s Disease and the Future Role of Value-Based Payment Arrangements

Contact Hours: 1.5. The current understanding of Alzheimer’s disease is evolving.

Alzheimer's

Member $15.00

Non-Member $30.00

Pulmonary Arterial Hypertension and the Managed Care Considerations for Formulary Decision-Making

Contact Hours: 1.25. Patients with pulmonary arterial hypertension (PAH) currently have a 60% five-year survival outlook, which has been increasing since the 1980s when it was a 37% five-year outlook.

Pulmonary Arterial Hypertension

Member Free

Non-Member $30.00

Rare Disease Therapies: Management Strategies to Pipeline Implications for Health Plans - Nexus 2017

Contact Hours: 1.5. The drug pipeline contains over 560 therapies in development for rare diseases.

Orphan Disease

Member $15.00

Non-Member $30.00

Real-Time Pharmacy Benefits: Results and Learnings from a Real-World Implementation

Contact Hours: 1.5. Real-time pharmacy benefits (RTPB) deliver real-time access to medication pricing and restriction information at the point of prescribing.

Real-TIme Pharmacy

Member Free

Non-Member $30.00

Real-World Experience Managing Orphan Drugs Across Pharmacy and Medical Benefits

Contact Hours: 1.25. Recently approved drugs for orphan diseases have annual costs ranging from $90,000 to over $1 million, while also having variable value propositions.

Orphan Disease

Main Catalog

Error